Zai Lab Limited Unsponsored ADR

ZLAB Healthcare Biotechnology

Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024. In the quarter to June 2026, revenue fell 3.33%, EPS fell 24.3%, free cash flow fell 84.4% and total debt rose 36.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

23.25 0.26 −1.11%
Market cap
$2.7B
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
4/9
Altman Z
−0.24
Beneish M
−2.35
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
4.72 4.60 4.20 8.46
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(33.47) (174.87) (74.25) (116.56)
P/B ratio
3.50 3.15 2.70 4.91
EV/Sales
3.65 3.39 2.93 7.07
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(10.11) (11.57) (8.21) (14.84)
Current Ratio
2.13 2.40 2.45 2.87
Net Debt/EBITDA
6.50 8.19 8.75 13.28
Debt/Equity
0.39 0.32 0.29 0.27
Earnings Yield
(9.00%) (8.61%) (9.13%) (5.75%)
Free Cash Flow Yield
(7.65%) (6.37%) (8.49%) (5.63%)
Free Cash Flow per Share
(0.58) (0.31) (0.25) (0.33)
Book value per Share
5.43 5.98 6.53 6.90
Free Cash Flow
(64.82) (34.20) (27.32) (36.09)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates